An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

NCT04215393 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Corneal Neovascularization

Interventions

DRUG: Conbercept eye drop
DRUG: Placebo

Sponsor

Chengdu Kanghong Biotech Co., Ltd.